Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeStance Health (LFST) EPS (Weighted Average and Diluted) (2021 - 2025)

LifeStance Health (LFST) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $0.03 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 250.0% to $0.03 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.02, a 112.5% increase, with the full-year FY2025 number at $0.02, up 113.33% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.03 for Q4 2025 at LifeStance Health, up from -$0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.03 in Q4 2025 to a low of -$0.35 in Q3 2021.
  • A 5-year average of -$0.12 and a median of -$0.12 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 54.55% in 2023, then soared 250.0% in 2025.
  • LifeStance Health's EPS (Weighted Average and Diluted) stood at -$0.33 in 2021, then skyrocketed by 60.61% to -$0.13 in 2022, then rose by 7.69% to -$0.12 in 2023, then surged by 83.33% to -$0.02 in 2024, then skyrocketed by 250.0% to $0.03 in 2025.
  • Per Business Quant, the three most recent readings for LFST's EPS (Weighted Average and Diluted) are $0.03 (Q4 2025), -$0.01 (Q2 2025), and -$0.02 (Q4 2024).